ERBB2 and breast carcinoma: Thus, 31% of the breast carcinoma patients analyzed with an AAb assay to a panel of TAAs comprised of MUC1, HER2, p53, and IGFBP2 had serum AAbs to at least one of the four TAAs tested, suggesting that diagnostic sensitivity may be improved by using AAb assay to a panel of TAAs for detection of breast carcinoma.